Page 1

☑Athira Athira Pharma Reports First Quarter 2021 Financial Results and Provides Business Highlights May 13 , 2021 -Phase 2 trial initiation for Parkinson's disease dementia program and IND submission for neuropsychiatric program planned by end of 2021- -Hosted educational webinar on targeting HGF / MET featuring leading neurologist Marwan Sabbagh , M.D- Raised $ 103.5M in follow - on public offering during first quarter of 2021 - BOTHELL , Wash . , May 13 , 2021 ( GLOBE NEWSWIRE ) -- Athira Pharma , Inc. ( NASDAQ : ATHA ) ( " Athira " ) , a late clinical - stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration , today reported financial results for the quarter ended March 31 , 2021 and provided recent business highlights . " We continue to execute on our corporate and clinical goals during this very important time in Athira's history , " said Leen Kawas , Ph.D. , President and Chief Executive Officer at Athira . “ Our clinical trials , ACT - AD and LIFT - AD , are actively enrolling and will evaluate the clinical utility of ATH - 1017 to treat Alzheimer's disease and improve cognitive health . In addition to developing ATH - 1017 in Alzheimer's disease , we plan to evaluate it in Parkinson's disease dementia . We also remain committed to advancing our expanding pipeline of novel , small molecule compounds . We have a well - defined strategic plan ahead of us and are well - funded to reach multiple clinical and regulatory milestones . " Recent Business Highlights and Anticipated Milestones Pipeline ATH - 1017 : A small molecule therapeutic specifically designed to enhance the activity of hepatocyte growth factor ( HGF ) and its receptor , MET , which are expressed in normal central nervous system function , in order to impact neurodegeneration and regenerate brain tissue . • ACT - AD trial is actively recruiting and is anticipated to report top - line data by early 2022 : Enrollment is proceeding for the randomized , placebo - controlled Phase 2 clinical trial evaluating ATH - 1017 , a once - daily investigational drug for the treatment of mild - to - moderate Alzheimer's disease . The trial plans to enroll approximately 75 patients in the United States and Australia . Over a treatment course of 26 weeks , participants will be evaluated for improvement in cognition , global and functional assessments comparing treatment arms to placebo . ACT - AD will also use electroencephalogram ( EEG ) to measure quantitative electroencephalogram ( qEEG ) and Event - Related - Potential ( ERP P300 ) , a functional measure of working memory processing speed and executive function . Results from the ACT - AD trial will inform the clinical development strategy for any additional trials of ATH - 1017 . • LIFT - AD trial is actively recruiting and is anticipated to report top - line data by the end of 2022 : Enrollment is proceeding for the randomized , double - blind , placebo - controlled Phase 2/3 clinical trial evaluating the safety , efficacy and tolerability of ATH - 1017 in individuals with mild - to - moderate Alzheimer's disease . The trial plans to enroll approximately 300 patients . Over a treatment course of 26 weeks , participants will be randomized across two dose groups and one placebo group . Clinical efficacy will be measured by improvement in cognition and global / functional assessments comparing treatment arms to placebo . • Phase 2 Parkinson's disease dementia trial on track to initiate at the end of 2021. Athira plans to initiate a Phase 2 trial of ATH - 1017 in patients with Parkinson's disease dementia by the end of 2021 . ATH - 1019 / 1020 : Novel , small molecule compounds designed to be orally available once - daily treatments , to activate the HGF / MET system and to distribute to the central nervous system as potential candidates for neuropsychiatric indications , including depression , anxiety and potentially schizophrenia . • IND filing expected by end of 2021. IND - enabling studies are proceeding for ATH - 1019 and ATH - 1020 . Athira is targeting an IND submission to the FDA by the end of 2021. Late - stage non - clinical development work and potentially early clinical studies will support decisions on selection of the lead product candidate and indication moving forward . Corporate • In April 2021 , Athira hosted an educational webinar on targeting HGF / MET , a naturally occurring , neuronal repair pathway . The webinar featured a presentation by Marwan Sabbagh , M.D. , a board - certified neurologist and geriatric neurologist and leading expert in Alzheimer's disease and dementia . Dr. Sabbagh discussed the current treatment